News

From Staff Reports Copyright © 2015 The Oklahoma Publishing Co. i2E Inc. and Accele Venture Partners recently closed a $600,000 follow-on investment in Synereca Pharmaceuticals, a portfolio company of Accele Biopharma, an Oklahoma City-based biotechnology accelerator. With the most recent investment, Synereca has now received $2.5 million in funding to support its development of compoundsRead more

Company focused on developing compounds to kill antibiotic-resistant bacteria Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 or email sseagraves@i2E.org i2E, Inc., recently closed on a $1.4 million seed capital investment in Oklahoma City-based Synereca Pharmaceuticals, which is developing ground-breaking compound that kills drug resistant bacteria. The investment was led by the i2E-managed OklahomaRead more